• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

April 14, 2021

View Archived Issues
Biotech deal illustration

Tango plans to join Nasdaq via Boxer-sponsored SPAC

Less than a year after landing a multibillion-dollar deal expansion with partner Gilead Sciences Inc., targeted cancer drug developer Tango Therapeutics Inc. is making moves to go public via a merger with Boxer Capital LLC-sponsored special purpose acquisition company BCTG Acquisition Corp. Read More

Romark eyes an EUA with new phase III COVID-19 outpatient data

“There is a big need for a drug in outpatients. If you could treat them and keep them out of hospitals, that would be important and play a big role in getting us through this pandemic,” Romark Laboratories LC’s CEO, Marc Ayers, told BioWorld. Read More
COVID-19 vaccine trial halted

J&J vaccine could be shelved a little longer

The current pause on administering Johnson & Johnson’s (J&J) one-dose COVID-19 vaccine likely will continue in the U.S. after the CDC’s Advisory Committee on Immunization Practices (ACIP) declined to make a recommendation on a path forward April 14. Read More

Drug developers lose market momentum in Q1

It has been a challenging opening first quarter for companies developing new therapeutics, with the BioWorld Drug Developers index recording a 9% drop in value, representing a stark contrast to its more than 35% growth last year. Read More
Cancer-cells-pic.png

New target identified for treatment-resistant CRC

Organoids cultured from patient-derived colorectal cancer cells have been used to demonstrate for the first time that tumors which have developed resistance to the full range of existing treatments, across chemotherapies, targeted therapies and immunotherapies, retain a requirement for Werner helicase (WRN) for survival. Read More

Scineuro licenses alpha-synuclein targeted antibodies from Lilly for greater China

Cross-border startup Scineuro Pharmaceuticals Ltd., which focuses on central nervous system (CNS) diseases, inked a deal with Eli Lilly and Co. to license in the greater China rights of alpha-synuclein-targeted antibody therapies to follow the global drug development trend in this space. Read More

Grants fall as nonprofit deals ascend; COVID-19 accounts for 26%

More than a quarter of all biopharma/nonprofit deals and grant awards in 2021, as well as 79% of the disclosed funding, targets the COVID-19 pandemic, following a trend that began in the early months of last year as SARS-CoV-2 reared its ugly head. Read More

House extends sequester moratorium

The latest global regulatory news, changes and updates affecting biopharma, including: FDA provides guidance on remote evaluations. Read More

Appointments and advancements for April 14, 2021

New hires and promotions in the biopharma industry, including: Aldevron, Coya, Hotspot, Lung, Ocugen, Pyramid, SAB, Sernova, Vivos. Read More

Conference data for April 14, 2021: AACR

New and updated preclinical and clinical data presented by biopharma firms at the American Association for Cancer Research Annual Meeting 2021, including: Adagene, Antengene, Ascentage, Beigene, Bluebird, Celcuity, Celldex, Eli Lilly, Geneleap, Greenwich, Heat, Immunocore, Immunogen, Innovent, Psioxus, Replimune, Sotio, Sound, Spectrum, SQZ, Sumitomo, Synthekine, Tachyon, Taiho, Tallac, TCR2, Theratechnologies, Treovir, Trisalus, Ultimovacs, Vincerx, Xencor, Y-mabs, Zentalis, Zymeworks. Read More

Financings for April 14, 2021

Biopharmas raising money in public or private financings, including: Advanced Proteome, Aruna, Bioversys, Humacyte, Immunoscape, Pasithea, Vascular Biogenics, Vectivbio. Read More

In the clinic for April 14, 2021

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Achieve Life Sciences, Agenus, Aligos, Ardelyx, Ascletis, Astrazeneca, Auris, Endo, Galectin, Gannex, Innocoll, Kyowa Kirin, Moderna, Nervgen, Orphomed, Proqr, Rocket, Romark, Synthetic Biologics and Veracyte. Read More

Other news to note for April 14, 2021

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Alimera, Amgen, Aquavit, Ardelyx, Atyr, Aura, Auris, Bioage, Biocryst, Bio-Techne, Boehringer Ingelheim, Cleveland Biolabs, Everon, Genome Protection, Hemogenyx, Huons, Immunicum, Innovation, Kyowa Kirin, Lonza, Merck & Co., Ocumension, Organicell, Polyneuron, Protokinetix, Rubryc, Stridebio, Taysha, Tilt, Torii, Xencor, Zai. Read More

Regulatory actions for April 14, 2021

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Amylyx, Astrazeneca, Cormedix, Gilead, Moleac, Moleculin, Praxis, Tetra. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 5, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 5, 2025.
  • DNA mutations or genetic disorder concept art

    Regenxbio’s Duchenne gene therapy data positive as shares falter

    BioWorld
    Regenxbio Inc.’s gene therapy in treating Duchenne muscular dystrophy (DMD) produced positive initial phase I/II results from its first five patients. However,...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • Woman holding neck

    Merus combo trounces Keytruda in head-and-neck phase II

    BioWorld
    Investor hopes rose sharply for Merus NV’s phase III trials – data should roll out next year – with bispecific antibody petosemtamab after mid-stage results...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe